Avexa sees widespread benefits in mid-stage HIV trial

Australia's Avexa is touting the results of a Phase IIb trial of its antiviral HIV drug apricitabine (ATC). Thirty-three patients were given two different doses of ATC, according to researchers, and all demonstrated marked improvement with at least an 85 percent reduction in HIV levels in the blood. ATC is being developed to treat patients who are drug-resistant. Phase III is slated to begin later this year and Avexa says it is confident that it can get the therapy on the market by 2010. Avexa is raising $60 million to begin commercial production of apricitabine.

"This is a fantastic result for Avexa," said CEO Dr. Julian Chick. "The positive result allows us to continue to progress ATC into Phase III trials and towards commercialization."

- see this release for more
- read the Herald Sun report

Related Articles:
Avexa gains rights to HIV drug. Report

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.